目的 評價玻璃酸鈉滴眼液聯(lián)合重組人表皮生長因子滴眼液霧化治療干眼癥的臨床治療效果和經(jīng)濟(jì)性，為臨床提供有效、安全、經(jīng)濟(jì)的干眼癥治療方案。方法 收集天津市眼科醫(yī)院2020年1月—2020年12月符合本研究制定的納入標(biāo)準(zhǔn)的124例中、重度干眼癥病例，將其分為2組：對照組接受玻璃酸鈉滴眼液聯(lián)合重組人表皮生長因子滴眼液局部點眼治療，治療組接受玻璃酸鈉滴眼液聯(lián)合重組人表皮生長因子滴眼液局部點眼治療的同時，加以霧化治療。以愈顯率為療效評價指標(biāo)，并運用成本-效果法對兩種不同的治療方案進(jìn)行經(jīng)濟(jì)學(xué)評價。結(jié)果 納入對照組和治療組的有效病例各62例。兩組愈顯率分別為56.45%、95.16%，有顯著性差異（P<0.05）。采用成本-效果分析可得，以對照組為基準(zhǔn)，增量成本效果比為7.29，治療組每獲得1%總有效率，需多支付7.29元，遠(yuǎn)低于意愿支付閾值（兩種治療方案平均總成本為276.83元），提示治療組的成本-效果性更佳。敏感性分析顯示兩組的成本效果相對于藥品價格及治療費用波動穩(wěn)定。結(jié)論 玻璃酸鈉滴眼液聯(lián)合重組人表皮生長因子滴眼液霧化治療，能夠顯著提高臨床療效，具有藥物經(jīng)濟(jì)學(xué)優(yōu)勢。

Objective To evaluate the clinical efficacy and economy of sodium hyaluronate eye drops combined with recombinant human epidermal growth factor eye drops in the treatment of xerophthalmia, so as to provide an effective, safe and economic treatment for xerophthalmia. Methods A total of 124 cases of moderate and severe xerophthalmia who met the inclusion criteria of this study in Tianjin Eye Hospital from January 2020 to December 2020 were collected and divided into 2 groups. The control group was treated with sodium hyaluronate eye drops combined with recombinant human epidermal growth factor eye drops for dropping, while the treatment group was treated with sodium hyaluronate eye drops combined with recombinant human epidermal growth factor eye drops for atomization and dropping. The cured + markedly effective rate was used as the evaluation index, and cost-effectiveness method was used to evaluate the economics of two different treatment schemes. Results 62 effective cases were included in the control group and the treatment group. The cured + markedly effective rate of the two groups were 56.45% and 95.16%, respectively, with significant difference (P<0.05). According to the cost-effectiveness analysis, the incremental cost-effectiveness ratio was 7.29 based on the control group, and the treatment group needed to pay 7.29 yuan more for every 1% total effective rate obtained, which was far lower than the desired payment threshold (the average total cost of the two treatment schemes was 276.83 yuan), suggesting that the treatment group had better cost-effectiveness. Sensitivity analysis showed that cost-effectiveness in both groups fluctuated steadily relative to drug prices and treatment costs. Conclusion The combination of sodium hyaluronate eye drops and recombinant human epidermal growth factor eye drops for atomization treatment can significantly improve the clinical efficacy and has the advantages of pharmacoeconomics.

R988.1